Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Sorry, there are no financial reports available yet.
Investor presentations
HCW Presentation September 13, 2021
Canaccord Presentation August 12, 2021
Wedbush Presentation August 11, 2021
HCW Presentation March 9, 2021
SVB Leerink Presentation Feb 24, 2021
JPM Presentation Jan 14, 2021
Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids
Investor Presentation Jefferies Virtual London Healthcare Conference November 18, 2020
Press Releases
ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November
press release
October 31, 2017
Geneva, Switzerland and Boston, MA – October 31, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Read moreObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors
press release
October 11, 2017
Geneva, Switzerland and Boston, MA – 10 October, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…
Read moreObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting
press release
September 11, 2017
Phase 1 clinical trial results in healthy subjects support cardiac safety of OBE022 Geneva, Switzerland and Boston, MA – 11 September, 2017 – ObsEva SA (NASDAQ: OBSV),…
Read moreGeneral Meetings
ObsEva Extraordinary General Meeting 2018
January 28, 2018
ObsEva Annual General Meeting 2017
June 13, 2017
Upcoming Events
Stock Information
Latest Press Release
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…
Read moreInvestor Contact
Media Contact
Media
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Media
Sign up for news
